The PLOS One editors have issued an expression of concern for a 2024 case study concerning the digital economy, innovation factor allocation and industrial structure transformation in China’s Yangtze River Delta city cluster. The notice, published on October 21, 2026, states that the article was identified as one of a series of submissions for which the journal has concerns about the integrity or reliability of the peer-review process. Readers are advised to interpret the original study with this issue in mind.

The notice does not report a new scientific finding, identify an error in the paper or evaluate the study’s scientific validity. According to the editors, PLOS did not assess the article’s integrity or scientific validity when following up on the matter. The expression of concern therefore records a concern about the circumstances surrounding peer review rather than announcing that the study’s data, methods or conclusions have been disproved. The editors also state that they have no concerns regarding the authors’ conduct during the peer-review process.

The affected article was published in PLOS One in 2024 under the title “Digital economy, innovation factor allocation and industrial structure transformation—A case study of the Yangtze River Delta city cluster in China.” The supplied notice does not provide the study’s findings, population details, analytical methods, model estimates, uncertainty measures or specific mechanisms linking the subjects named in the title. As a result, the notice does not support conclusions about the relationship between digital-economy development, innovation factors and industrial structure in the region, nor does it establish whether any reported association or causal effect is reliable.

For the wider research record, the immediate effect is that the 2024 article is accompanied by an editorial notice questioning the integrity or reliability of its peer-review process. The notice does not provide details about the submissions or explain the specific basis for the journal’s concerns. It also does not announce a correction, replacement analysis or revised conclusion. The central status of the paper’s scientific validity remains unevaluated in the supplied material, while the issue is sufficiently significant for PLOS One to advise readers to consider it when interpreting the study.

Subject of Research: A PLOS One expression of concern concerning peer-review reliability in a Yangtze River Delta regional-economy case study.

Article Title: Expression of Concern: Digital economy, innovation factor allocation and industrial structure transformation—A case study of the Yangtze River Delta city cluster in China

Article References: The PLOS One Editors (2026). Expression of Concern: Digital economy, innovation factor allocation and industrial structure transformation—A case study of the Yangtze River Delta city cluster in China. PLOS One, 21(10), e0360867. https://doi.org/10.1371/journal.pone.0360867

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360867

Keywords: PLOS One, expression of concern, peer review, research integrity, digital economy, innovation factors, industrial structure, Yangtze River Delta, China, Expression, Concern, Digital

In one of the most comprehensive investigations of its kind, researchers have taken a major step toward untangling the biology underlying suicide risk, moving the field beyond long-standing debates about whether suicidal behavior is simply a consequence of psychiatric illness. By integrating large-scale genetic data with cutting-edge approaches that map how genes act in specific brain cells and circuits, an international team has identified shared genetic liability that cuts across psychiatric diagnoses while also pinpointing druggable biological pathways that could one day inform prevention strategies. The study, published in Translational Psychiatry, offers a sweeping synthesis of how inherited risk factors may translate into molecular vulnerabilities, and it does so with a level of resolution that previous candidate-gene approaches could never achieve.

Suicide remains one of the leading causes of death worldwide, claiming more than 700,000 lives each year according to global health estimates. Despite decades of research, clinical prediction remains stubbornly imprecise, and biological models of suicidal behavior have historically been hampered by small sample sizes, inconsistent findings, and a tendency to conflate suicide risk with the psychiatric disorders with which it so often co-occurs. Major depression, bipolar disorder, schizophrenia, and substance use disorders all carry elevated suicide risk, yet most people with these conditions never attempt suicide, while some individuals who die by suicide have no diagnosed psychiatric illness at all. This paradox has long suggested to researchers that suicidal behavior may possess partially distinct biological underpinnings, and the new study set out to test that hypothesis with unprecedented statistical power.

At the heart of the work lies genome-wide association study methodology, or GWAS, which scans hundreds of thousands to millions of genetic variants spread across the entire genome in very large groups of people, comparing individuals who have experienced suicidal thoughts or behaviors with those who have not. Each variant is tested for statistical association with the outcome, and the results can be combined into polygenic risk scores, numerical summaries of a person’s inherited liability based on the cumulative small effects of thousands of variants. Because no single common variant exerts a large effect, the field depends on aggregating data across massive biobanks and cohorts, a strategy that has only become feasible in the past decade as datasets containing hundreds of thousands of individuals became available.

The research team took particular care to address a central confound: psychiatric disorders themselves are highly heritable, and any genetic signal linked to suicide could simply reflect inherited liability to depression or schizophrenia rather than to suicide specifically. To disentangle this, the investigators applied sophisticated statistical techniques, including genetic correlation analysis and conditional modeling, which allow researchers to ask how much genetic overlap remains between suicidal behavior and psychiatric conditions after accounting for their shared heritability. Their findings revealed a complex architecture. Substantial genetic correlations confirmed that suicide risk shares a meaningful fraction of its inherited basis with major psychiatric disorders, supporting the idea of a common pool of genetic liability. Yet the analyses also uncovered signals that persisted beyond what could be explained by those disorders, pointing to biological mechanisms that may be more specific to the emergence of suicidal thoughts and actions.

A key conceptual innovation of the study is its framing of “shared genetic liability” as a bridge between diagnoses. Rather than treating suicide as an epiphenomenon of any single disorder, the researchers modeled it as a transdiagnostic phenomenon, one whose risk emerges partly from inherited vulnerabilities that cut across diagnostic categories. This perspective aligns with a growing movement in biological psychiatry that emphasizes symptom dimensions and mechanisms over traditional diagnostic boundaries. From this vantage point, the genetic variants that raise risk for depression, PTSD, and schizophrenia may do so partly because they converge on shared molecular pathways, and those same pathways may govern an individual’s threshold for suicidal crises regardless of which diagnosis they carry.

Identifying genetic variants, however, is only the first step. A GWAS signal typically points to a genomic region rather than a specific causal gene or mechanism, since many associated variants fall in non-coding stretches of DNA that regulate gene activity from a distance. To translate statistical associations into biological insight, the team deployed a battery of functional genomics approaches. Transcriptome-wide association studies, known as TWAS, integrate gene expression data to identify genes whose genetically predicted expression levels are linked to suicide risk. Tissue and cell-type enrichment analyses then ask whether the implicated genes are unusually active in particular organs or cell populations. The results converged strikingly on brain tissue, and more specifically on neuronal populations, providing support for the idea that inherited suicide risk is mediated largely through gene regulation within the central nervous system.

The study’s most clinically provocative findings concern druggable biology. Using databases that catalog the protein targets of approved and investigational medications, the researchers examined whether genes implicated in suicide risk were over-represented among known drug targets. The analysis identified several classes of candidate targets, including components of neurotransmitter signaling systems, ion channels, and intracellular signaling cascades that are already the focus of pharmacological development for other conditions. This “druggable genome” approach, which has gained traction in genetics research across many diseases, offers a pragmatic shortcut for translational science: rather than waiting decades for entirely new therapeutic classes to be invented, researchers can prioritize existing or in-development compounds whose molecular targets intersect with genetically implicated pathways.

Among the pathways receiving attention in the analysis were those involving glutamatergic and GABAergic neurotransmission, the primary excitatory and inhibitory systems of the brain, which have repeatedly surfaced in studies of mood disorders and stress response. The endocannabinoid system and inflammatory signaling pathways also appeared in the convergent analyses, consistent with a broader literature linking immune dysregulation and allostatic load to suicidal ideation. Importantly, the authors emphasize that these findings identify hypotheses rather than ready-made treatments. Genetic association with a drug target does not guarantee that modulating that target will reduce suicide risk, and any therapeutic application would require extensive preclinical validation and carefully designed clinical trials. Nevertheless, the work provides a principled, data-driven map for where to look, replacing decades of largely failed candidate-gene speculation with a genome-wide evidence base.

The methodological rigor underpinning the study deserves emphasis, because the genetics of suicidal behavior has a troubled history. Early candidate-gene studies, which typically examined a handful of variants in genes related to serotonin signaling, produced findings that largely failed to replicate and in some cases were later shown to reflect statistical artifacts, small samples, and publication bias. The field has since undergone a reckoning, and modern efforts adhere to far stricter standards: preregistered analyses, very large and ancestrally diverse cohorts, replication in independent samples, and conservative multiple-testing corrections that demand genome-wide significance thresholds on the order of five times ten to the negative eighth power. The new study reflects these lessons, applying sensitivity analyses to guard against confounding from psychiatric comorbidity and examining whether findings generalize across ancestral groups, an issue of considerable importance given that most genetic discovery to date has been conducted in populations of European ancestry.

The implications for clinical practice, while still distant, are worth considering. Polygenic risk scores for suicide-related outcomes currently explain only a small fraction of individual differences in risk, far too little to be used as stand-alone screening tools, and their predictive performance is degraded in populations not represented in the discovery data. Researchers in the field are careful to stress that genetic risk is not destiny: suicidal behavior arises from an intricate interplay of inherited vulnerability, mental illness, trauma, substance use, social isolation, access to lethal means, and the availability of support. What genetics offers is not a crystal ball but a window into mechanism, and mechanistic knowledge is the raw material from which better biomarkers, risk stratification tools, and ultimately targeted interventions are built. In the near term, the druggable pathway findings are most valuable as a guide for laboratory science, directing neurobiologists toward molecular systems whose manipulation might alter suicide-relevant phenotypes in animal models and cellular assays.

Looking forward, the study signals where the field must go next. Sample sizes for suicide-specific genetic analyses remain smaller than those for major psychiatric disorders, and expanding representation across ancestries is essential if the benefits of this research are to be shared equitably. Integrating genetic data with longitudinal measures of life stress, neural imaging, and digital phenotyping may eventually allow researchers to model how inherited liability interacts with environmental triggers across the lifespan. Functional experiments in induced pluripotent stem cell-derived neurons and brain organoids could test whether the implicated genes genuinely alter stress-response circuitry or resilience. And randomized trials in patients carrying high genetic liability, though ethically and logistically complex, represent the logical endpoint of the druggable-target approach.

What the study ultimately delivers is a reframe. Suicide risk, in this analysis, is not an amorphous clinical outcome but a measurable, partly heritable trait whose genetic architecture is now being resolved with the same tools that have transformed our understanding of heart disease, diabetes, and schizophrenia. By demonstrating that shared genetic liability links suicide risk across diagnostic boundaries and by mapping that liability onto specific, pharmacologically tractable biology, the researchers have converted a long-standing clinical puzzle into a concrete research agenda. The path from genetic correlation to effective prevention is long, and no genetic finding will soon replace the human work of crisis intervention, connection, and care. But for a problem that has defied biological explanation for generations, the identification of shared, druggable mechanisms represents a genuine and hard-won advance, one that may shape suicide research for years to come.

A short-term decision to eat fewer or no animal products may begin reshaping the human body at the molecular level far sooner than many people expect, according to a new study published in Nature Communications. Research by A. Simistiras, O. Bocher, C. Emmanouil and colleagues examined how restricting animal-derived foods affects both gene activity and protein production in humans, revealing a complex biological response that unfolds beneath the visible changes on a plate.

The study focuses on proteogenomics, an approach that combines two powerful layers of biological information. Genomics and transcriptomics examine the instructions encoded in DNA and the messenger RNA molecules produced when genes are activated. Proteomics, by contrast, measures the proteins that cells actually manufacture. Because proteins perform most of the body’s day-to-day work—from transporting nutrients to controlling immune reactions—studying them alongside gene activity can provide a more direct picture of how physiology responds to dietary change.

Rather than treating diet as a distant influence on long-term health, the research highlights it as an immediate biological signal. When people reduce their intake of animal products, the body is exposed to a different mixture of amino acids, fats, vitamins, minerals and other bioactive compounds. The quantity and timing of these nutrients can alter metabolic pathways, cellular signaling and the activity of genes involved in maintaining tissues. The researchers’ proteogenomic analysis was designed to capture these interconnected effects during a relatively short dietary intervention.

The significance of the work lies in its ability to distinguish between what cells are instructed to do and what they ultimately do. A gene may become more active without producing a corresponding increase in its protein, while a protein may remain stable because of slower turnover or regulation after translation. By examining both molecular layers, the study offers a more refined view of diet-responsive biology than either gene-expression or protein measurements alone. This is particularly important for nutrition research, where modest changes in multiple pathways can combine to influence health.

The findings indicate that restricting animal products can produce measurable molecular shifts even over a limited period. These changes do not represent a simple biological switch from “animal-based” to “plant-based” physiology. Instead, they appear as a network of coordinated responses involving nutrient processing, energy metabolism and cellular regulation. Some proteins may respond directly to altered nutrient availability, while others may change indirectly as tissues adapt to new metabolic demands. The result is a biological signature of dietary transition rather than a single marker that explains every effect.

Such signatures could eventually help researchers understand why individuals respond differently to the same eating pattern. Two people can consume similar diets yet experience distinct changes in blood chemistry, metabolism or immune activity because of differences in genetics, gut microorganisms, age, lifestyle and baseline health. Proteogenomic profiles may help identify these sources of variation by showing which pathways are activated in each person. In the future, that information could support more individualized nutritional guidance instead of assuming that one dietary pattern produces the same outcome for everyone.

The study also underscores an important distinction between molecular response and clinical benefit. Detecting changes in proteins or gene activity does not automatically prove that a diet will prevent disease, improve performance or extend lifespan. Molecular alterations can be adaptive, neutral or potentially harmful depending on their intensity, duration and biological context. The research therefore provides evidence that the body responds rapidly to dietary restriction, while longer and larger studies will be needed to determine how these responses relate to cardiovascular health, metabolic disease, immune function and other outcomes.

The work arrives as plant-forward diets are drawing increasing interest for environmental, ethical and health reasons. Yet public discussions often reduce the science to competing claims about whether animal products are categorically beneficial or harmful. The proteogenomic perspective offers a more nuanced alternative. It suggests that dietary effects emerge through dozens, perhaps hundreds, of interacting pathways, and that the consequences of removing or reducing a food category depend on what replaces it. A diet rich in minimally processed legumes, grains, nuts, seeds, fruits and vegetables may produce a very different molecular response from one dominated by refined plant-based products.

For scientists, the study demonstrates the value of observing dietary change across multiple biological scales. For the public, its message is both striking and practical: the body does not wait years to notice what people eat. Even short-term restriction of animal products can be reflected in the molecular machinery of human cells. The findings do not settle the broader debate over the ideal diet, but they add a new layer of evidence showing that food choices are rapidly translated into biological signals—and that understanding those signals may be key to designing healthier, more personalized nutrition strategies.

Subject of Research: The proteogenomic effects of short-term restriction of animal products in humans.

Article Title: Diet-responsive proteogenomic effects following short-term restriction of animal products in humans.

Article References: Simistiras, A., Bocher, O., Emmanouil, C. et al. Diet-responsive proteogenomic effects following short-term restriction of animal products in humans. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76379-6

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76379-6

Keywords: proteogenomics, nutrition, animal-product restriction, plant-based diet, gene expression, protein response, human metabolism, dietary intervention, precision nutrition

John Voorhees:

What sets Pastebot 3 apart is its addition of deep automation tools. Not only does the update add MCP support, making it an excellent tool to use with Claude or ChatGPT/Codex, but it includes a brand new CLI that you or an agent can use from Terminal or incorporate into scripts you build.

[…]

New filters have been added that allow you to transform clippings using text transformations and even shell scripts. Using the ability to script custom filters, I’ve begun adding a few of my own to Pastebot for things like adding and removing bullets from multiple lines of text.

I’ve long been aware of this app but hadn’t paid much attention because I’m happy using LaunchBar as my clipboard and snippet manager. LaunchBar has some transformations built-in, and I’ve built up a collection of my own scripts, but it’s appealing that Pastebot comes with so many out of the box.

From Pastebot’s main UI, you can select multiple items at once and right-click to add them to a Stack, or you can pick them one at a time in any order you’d like. As you select items, they’re numbered in the order you’ll paste them into a document using a keyboard shortcut. It’s an excellent feature for filling out forms or copying data from one spreadsheet to another.

Juli Clover:

There are also rule-based Smart Pastebins for automatic organization, like every link or image copied from Safari. Smart Pastebins can be filtered by clipping size, type, file extension, creation date, text, text length, and more. Multiple parameters can be combined for detailed filtering, and custom notes can be added to clippings to make them easy to find via search.

[…]

Tapbots says Pastebot 3 was built to work with Apple's Universal Clipboard feature, and when enabled and active, anything you copy on your iPhone is saved in Pastebot automatically.

John Gruber:

Chief among my favorite features:

• Remembers up to 1,500 clippings (up from a mere 1,000 in v2).
• Syncs via iCloud. If I copy something on one Mac, it’s in my Pastebot history on my other Macs.
• That sweet Tapbots UI.

Marcus Mendes:

Importantly, Pastebot 3 requires macOS 26 Tahoe or later and comes with a 14-day free trial. Users can buy the app directly from Tapbots for $39 or subscribe through the App Store for $2.99 per month or $24.99 per year.

[…]

The direct purchase includes one year of updates, with additional years available for $19 each. Users who stop paying for updates can continue using the latest version covered by their purchase. Pastebot 2 owners can also get a $12.99 upgrade discount by entering their existing license key at checkout.

scottybee:

They are not offering any upgrade path for MAS customers. The reason they stated was “upgrade pricing has always been our way of thanking people who bought directly from the site.”

Paul Haddad:

I generally try to avoid complaining about App Store review, since I do think they have a really hard job to do. But I’m about 2 more PB3 rejections from just giving up.

Previously:

• Apple’s Spotlight Clipboard Manager
• Boop 1.3.1
• Processing the Selected Text via Script
• iOS Background App Kludge

Recent breakthroughs in neuropsychiatric research have brought to light remarkable insights into the molecular underpinnings of bipolar disorder (BD) and major depressive disorder (MDD), two of the most debilitating mood disorders worldwide. In an ambitious study published in Translational Psychiatry, Gao, Otsuka, Shirai, and colleagues harnessed the power of postmortem brain tissue analysis, combining single-nucleus RNA sequencing with traditional bulk gene expression techniques. Their pioneering work revealed intricate shared and distinct neuropathological alterations between these disorders, carving a new path for understanding their complex biology on an unprecedented scale.

Bipolar disorder and major depressive disorder are notoriously challenging to differentiate clinically, with overlapping symptoms but divergent treatment responses, underscoring the urgent need for molecular markers that delineate their neurobiological distinctions and commonalities. The investigators obtained postmortem brain specimens from multiple brain regions critically involved in mood regulation, including the prefrontal cortex and hippocampus, to delineate cell-type-specific transcriptomic changes that contribute to these psychiatric conditions.

A key innovation in this study was the utilization of single-nucleus RNA sequencing, a cutting-edge technique that isolates nuclei from archived frozen brain tissue, enabling fine-grained analysis of gene expression at single-cell resolution. This approach circumvents the issue of cellular heterogeneity within bulk tissue samples, revealing how discrete neuronal and glial populations are differentially affected in BD and MDD. By integrating single-nucleus and bulk RNA-seq data, the research team robustly characterized both cell-type-specific expression patterns and more global transcriptomic signatures associated with mood disorders.

The results illuminated both convergent and divergent pathological processes. For instance, inflammatory responses and synaptic signaling pathways were dysregulated across both BD and MDD, suggesting common neuroimmune mechanisms contributing to mood dysregulation. However, certain pathways, such as mitochondrial function and calcium signaling, exhibited distinct alterations exclusive to bipolar disorder, potentially explaining its episodic mood swings and treatment resistance. Conversely, dysregulation in neuroplasticity-related genes was more prominent in major depressive disorder, providing molecular evidence for the chronic and often treatment-resistant nature of depressive states.

In particular, inhibitory interneurons, which play a pivotal role in maintaining excitatory/inhibitory balance within cortical circuits, showed altered gene expression profiles predominantly in the bipolar disorder samples. These perturbations may underlie the episodic manic and depressive phases characteristic of BD, by disrupting cortical oscillations and neuronal synchrony. Contrastingly, astrocytes and microglial cells prioritized in the depressive brain tissue exhibited genes consistent with a pro-inflammatory phenotype and impaired support for neuronal survival and plasticity.

Intriguingly, the study identified a set of “hub” genes with altered expression patterns that are common to both disorders, interfacing with known psychiatric risk loci from genome-wide association studies. These genes appear to orchestrate complex networks involving neuroinflammation, neurotransmission, and cellular metabolism, positing them as potential therapeutic targets that could modulate trajectories of mood disorder progression. Such convergence strengthens the conceptualization of mood disorders as spectrum diseases sharing overlapping pathogenic pathways.

The authors further investigated how chronic mood symptoms might imprint on gene expression by comparing early versus late-stage individuals with BD and MDD. Progressive dysregulation in synaptic and mitochondrial genes suggested a cumulative neurobiological burden, providing molecular correlates for illness chronicity and cognitive decline observed clinically. This temporal dimension paves the way for identifying early biomarkers and intervention windows before irreversible neuropathology ensues.

Advanced computational modeling and network analyses underscored the power of integrating multi-omic datasets for unraveling neuropsychiatric complexity. By employing weighted gene co-expression network analysis, the team uncovered modules heavily enriched for cell-type-specific functions altered in mood disorders. This systems biology perspective highlights how individual gene changes ripple through interconnected pathways, culminating in the multifaceted symptomatology seen in BD and MDD.

Importantly, this research leveraged well-characterized human brain samples, overcoming the limitations of animal models which frequently fail to recapitulate the full spectrum of human mood disorder biology. Postmortem studies like this bridge the translational gap, anchoring preclinical findings to human pathology and enhancing the relevance and precision of future therapeutic development.

The implications for treatment are manifold. Identifying distinct molecular signatures opens avenues for personalized medicine, enabling clinicians to tailor interventions based on an individual’s unique gene expression profile. For example, therapeutics targeting mitochondrial dysfunction may benefit BD patients exhibiting specific transcriptomic disturbances, while anti-inflammatory strategies could be prioritized for MDD cases marked by neuroimmune dysregulation.

Looking forward, the integration of single-nucleus transcriptomics with other emerging modalities—such as epigenomic mapping, spatial transcriptomics, and proteomics—promises to construct even richer cellular atlases of the human brain in health and disease. These comprehensive data layers will be instrumental in deciphering the dynamic interplay of genes, environment, and neural circuitry that culminate in complex psychiatric illnesses.

This study by Gao and colleagues represents a landmark in neuropsychiatric research by elegantly demonstrating how advanced genomic technologies can dissect heterogeneity within and between mood disorders at an unparalleled resolution. Such mechanistic insights are crucial for the rational design of next-generation therapeutics with improved efficacy and fewer side effects, addressing the considerable unmet needs in mental health care.

Beyond its scientific merit, this research challenges existing diagnostic frameworks, advocating for a biology-driven reclassification of mood disorders that transcends symptomatic overlap. As psychiatric medicine moves toward precision psychiatry, findings like these underscore the urgent imperative to redefine mental illnesses based on molecular pathology rather than solely clinical presentation.

In conclusion, by unveiling both shared and distinct transcriptomic landscapes of bipolar disorder and major depressive disorder, this landmark study illuminates the molecular intricacies underlying these enigmatic illnesses. It sets a new gold standard for postmortem brain research and opens transformative pathways toward more effective diagnostics and interventions that can profoundly improve the lives of millions suffering from mood disorders globally.

Subject of Research: Molecular and cellular abnormalities in bipolar disorder and major depressive disorder as revealed by postmortem brain single-nucleus and bulk gene expression analyses.

Article Title: Postmortem brain single-nucleus and bulk gene expression analyses identify shared and distinct abnormalities in bipolar disorder and major depressive disorder.

Article References:
Gao, R., Otsuka, I., Shirai, T. et al. Postmortem brain single-nucleus and bulk gene expression analyses identify shared and distinct abnormalities in bipolar disorder and major depressive disorder. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04200-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04200-5

In the rapidly advancing field of assisted reproductive technologies (ART), subtle biochemical cues during treatment cycles can have profound and lasting impacts on offspring health. A groundbreaking study by Jiang, Wei, Liu, and colleagues, set to appear in Nature Communications in 2026, reveals intricate links between human chorionic gonadotropin (hCG) exposure on the trigger day of ART protocols and enduring epigenetic modifications that influence neurodevelopmental trajectories in children conceived via these methods. This research shines a spotlight on the complex interplay between hormonal interventions during ART and the epigenetic landscape shaping long-term neurodevelopmental outcomes.

At the core of this investigation lies hCG, a glycoprotein hormone traditionally recognized for its critical role in early pregnancy maintenance. It is clinically administered as a trigger to induce final oocyte maturation and subsequent ovulation in ART cycles. Despite its widespread use, the broader biological consequences of hCG administration timing and dosage, particularly regarding the epigenome of resulting embryos and offspring, remain poorly understood. Jiang and colleagues address this knowledge gap by systematically evaluating how hCG exposure on trigger day affects DNA methylation patterns—a key epigenetic mechanism regulating gene expression—in offspring conceived via ART.

Utilizing a large cohort of ART offspring and sophisticated epigenomic profiling techniques, the researchers uncovered that variations in trigger-day hCG levels corresponded to distinct DNA methylation signatures detectable in peripheral tissues of the children years post-birth. These methylation changes were not random but localized to genes with established roles in neurodevelopment and synaptic function. Notably, altered methylation was observed in loci involved in neuronal proliferation, differentiation, and synaptic plasticity, processes fundamental to cognitive development and neurological health.

The implications of these findings are considerable given the rising prevalence of ART-conceived individuals globally. Epigenetic modifications such as DNA methylation are dynamic yet heritable through cell division, and perturbations during critical windows of embryonic development can have cascading effects on gene regulation. Jiang et al.’s data suggest that the timing and hormonal milieu created by hCG administration on trigger day may inadvertently shape the epigenetic program of the embryo with consequences extending into postnatal brain development.

To unravel the potential neurodevelopmental consequences, the team correlated their epigenetic data with standardized neuropsychological assessments performed on the ART offspring. They reported significant associations between specific methylation patterns and measures of cognitive function, executive processing, and social behavior, domains frequently implicated in neurodevelopmental disorders. This links the biochemical intervention in ART directly to behavioral phenotypes observed in the children, underscoring the functional relevance of epigenetic imprinting driven by hCG exposure.

Mechanistically, the study posits that hCG triggers a cascade of intracellular signaling events including modulation of DNA methyltransferase (DNMT) activity and chromatin remodelers during oocyte maturation and early embryo development. These processes may alter the establishment or maintenance of methylation marks at neurodevelopmentally critical genes. Interestingly, variations in the hCG dose and timing created distinct epigenomic landscapes, emphasizing the fine balance required in ART hormone protocols to avoid unintended epigenetic dysregulation.

This research not only advances understanding of ART-associated neurodevelopmental risks but also offers actionable insights for clinical practice. Optimizing hCG administration parameters could mitigate adverse epigenetic and developmental outcomes, enhancing the safety profile of ART. The notion that a single hormonal manipulation at a specific time point can induce persistent epigenomic and neurodevelopmental alterations demands a reevaluation of ART protocols incorporating epigenetic endpoints.

The findings may also have broader implications beyond ART, revealing fundamental principles of how transient hormonal milieus during early development can imprint long-lasting changes on gene regulation and phenotype. This could inform developmental biology, neuroepigenetics, and endocrine research, potentially identifying biomarkers predictive of neurodevelopmental risk across diverse prenatal exposures.

Furthermore, the study leverages cutting-edge epigenomic technologies such as whole-genome bisulfite sequencing and single-cell methylation analysis, coupled with rigorous neurobehavioral phenotyping in a longitudinal cohort framework. This integrative, multi-omics approach sets a new standard for assessing the safety and long-term effects of reproductive interventions, blending molecular precision with clinical relevance.

Ethically, these insights prompt a dialogue about the need for comprehensive monitoring of ART offspring, integrating epigenetic screening and neurodevelopmental surveillance to detect and potentially intervene in early deviations. The epigenetic alterations detected by Jiang et al. are reversible in principle, raising the prospect of targeted epigenetic therapies or nutritional interventions to restore typical developmental trajectories.

Moreover, the study encourages further exploration into paternal contributions and environmental factors interacting with trigger-day hCG effects, recognizing that ART outcomes emerge from a complex interplay of genetics, epigenetics, and external exposures. Identifying modifiers of hCG-induced epigenetic programming could refine personalized ART approaches tailored to individual risk profiles.

Overall, this landmark research by Jiang and colleagues opens a new frontier in reproductive medicine, illustrating that the endocrinology of ART cycles extends beyond immediate gamete maturation to sculpt the epigenomic and neurodevelopmental fate of future generations. It reinforces the imperative for precision medicine in reproductive technologies and highlights the power of epigenetics in mediating early-life environmental influences on human development.

As ART continues to bring hope to millions struggling with infertility, understanding and controlling the subtle molecular ripples of treatment interventions like hCG administration becomes paramount. Jiang et al.’s study sets a vital precedent, demonstrating that optimizing hormone triggers is not merely a matter of improving pregnancy rates but safeguarding the neurological health and well-being of ART-conceived individuals throughout their lives.

Subject of Research: Human chorionic gonadotropin (hCG) effects on DNA methylation and neurodevelopment in offspring conceived via assisted reproductive technologies (ART).

Article Title: Trigger-day hCG effects on DNA methylation and neurodevelopment in ART offspring.

Article References:
Jiang, Y., Wei, X., Liu, X. et al. Trigger-day hCG effects on DNA methylation and neurodevelopment in ART offspring. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74712-7

Image Credits: AI Generated

In a groundbreaking advancement that could reshape the landscape of molecular biology, researchers have unveiled a high-resolution method for single-cell sequencing of trans-spliced mRNA, setting new benchmarks in cellular transcriptomics. This state-of-the-art technique, detailed in a recent publication by Cosentino and colleagues, promises unprecedented insight into the complex mechanisms governing RNA splicing and gene expression at a single-cell level, a domain critical for understanding diverse biological processes and disease states.

Traditional RNA sequencing methods often struggle to capture the nuances of trans-splicing—an RNA processing event where exons from different pre-mRNA molecules are joined together. This unique form of splicing has been relatively underexplored, largely due to technical limitations in distinguishing trans-spliced variants from the more common cis-spliced transcripts. The innovation presented in this protocol addresses these challenges head-on by incorporating enhanced molecular tagging and amplification strategies to faithfully preserve the native architecture of trans-spliced mRNAs.

The power of single-cell sequencing lies in its ability to discern cellular heterogeneity that bulk sequencing methods average out. By applying this resolution to trans-splicing events, the new protocol enables researchers to map how individual cells harness this process to diversify their transcriptomes. This can reveal regulatory layers previously masked in population-level analyses, providing clues about cell type-specific functions, developmental trajectories, and responses to environmental stimuli.

Central to the protocol’s success is its meticulous capture of the transcript’s 5’ and 3’ ends, allowing unambiguous identification of trans-spliced junctions. The approach leverages novel enzymatic reactions and ligation steps carefully optimized to maintain sequence integrity, enabling high-fidelity reconstruction of splicing landscapes. Moreover, the method integrates seamlessly with established single-cell RNA sequencing platforms, widening accessibility and potential for widespread adoption.

The practical implications of this development are vast. Researchers can now probe the role of trans-splicing in normal physiology and pathogenesis with precision. Given that aberrant RNA splicing is implicated in various cancers and genetic disorders, understanding trans-splicing patterns at the single-cell level could illuminate new biomarkers and therapeutic targets. Furthermore, tissues with complex cell compositions, such as the brain or immune system, stand to benefit profoundly from this refined analytical lens.

Implementing this protocol requires meticulous experimental execution. Steps include cell isolation, mRNA extraction under conditions preserving RNA integrity, strategic reverse transcription with specialized primers, as well as a series of purification and amplification cycles designed to enrich for trans-spliced sequences. Each phase has been rigorously characterized to maximize sensitivity and specificity, ensuring reproducible outcomes across diverse sample types.

Bioinformatic analysis pipelines accompanying the protocol are equally sophisticated. They employ advanced algorithms capable of distinguishing genuine trans-splicing events from experimental artifacts or sequencing errors. These computational tools facilitate high-confidence annotation of transcripts, visualization of splicing diversity, and quantification of junction abundance at single-cell resolution, pushing the analytical frontier forward.

Beyond capturing static snapshots, the technology opens pathways to dynamic studies. Scientists can track how trans-splicing activity varies during cellular differentiation, in response to external cues, or throughout disease progression. This temporal dimension adds a vital layer of understanding to RNA biology’s functional repertoire, potentially revealing regulatory checkpoints amenable to therapeutic modulation.

The introduction of this high-resolution sequencing method also underscores the increasing convergence of experimental and computational biology. It reflects a growing recognition that unraveling complex molecular phenomena demands integrated approaches combining cutting-edge laboratory techniques with robust data science. This synergy not only accelerates discovery but democratizes access to intricate biological insights.

Intriguingly, this approach may shed light on evolutionary aspects of splicing. Differences in trans-splicing prevalence and patterns across species and cell types could inform hypotheses about RNA processing’s adaptive significance. Delineating these evolutionary narratives may provide broader context for interpreting functional data and guiding synthetic biology applications.

Moreover, the methodology’s adaptability hints at future expansions. For example, coupling this protocol with spatial transcriptomics could map trans-spliced mRNAs within tissue architecture, or integrating with proteomics could link transcript variants to protein isoform expression. Such multidimensional analyses hold promise for unraveling the intricate web connecting genotype to phenotype.

As research workflows adopt this technology, anticipated challenges include managing increased data complexity and scaling up throughput for large single-cell atlases. Nonetheless, the benefits—unveiling the hidden layers of transcriptomic regulation with unprecedented clarity—far outweigh these hurdles. The authors’ thorough validation in diverse biological contexts allays concerns about adaptability and robustness.

Ultimately, this state-of-the-art protocol propels trans-splicing research to new heights, furnishing the scientific community with a versatile toolset to decode RNA’s role in health and disease at unparalleled resolution. It exemplifies a milestone where technological ingenuity meets biological inquiry, heralding a new era in transcriptomic sciences.

As this methodology gains traction, it is poised to catalyze transformative discoveries, deepen our molecular understanding, and inspire follow-up innovations. The potential ripple effects extend from basic science to clinical diagnostics, underlining the enduring impact of pioneering single-cell approaches in unlocking cellular complexity comprehensively.

Subject of Research: High-resolution single-cell sequencing of trans-spliced mRNA

Article Title: High-resolution single-cell sequencing of trans-spliced mRNA

Article References:
Cosentino, R.O., Keneskhanova, Z., Esser, S. et al. High-resolution single-cell sequencing of trans-spliced mRNA. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01373-7

DOI: https://doi.org/10.1038/s41596-026-01373-7

Image Credits: AI Generated